Falciparum Malaria Clinical Trial
Official title:
Safety, Feasibility, and Endothelial Effects of Sodium Nitrite Infusion in Children With Falciparum Malaria
Verified date | January 2021 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety of intravenous sodium nitrite in African children who have moderately severe malaria.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 1, 2021 |
Est. primary completion date | October 1, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 4 Years to 10 Years |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent from parent or legal guardian 2. Males, >4 to 10 years of age 3. Body weight > 12 kg 4. Parasitemia with Plasmodium falciparum including: 1. Positive rapid diagnostic test result: AND 2. >2,500 parasites/microliter by microscopy 5. Diagnosis of MSM, as follows: 1. Clinical syndrome consistent with malaria associated with documented fever (axillary temperature >38C) or reported history of fever in the past 48 hours with no other cause present; AND 2. Exhibiting no WHO warning signs or criteria for SM [27] 6. A negative G6PD deficiency test (careSTART G6PD quantitative biosensor) 7. Requires inpatient parenteral treatment because of inability to tolerate oral therapy 8. Hemoglobin > 8 g/dL (subjects with prior blood transfusion will be eligible). 9. Systolic blood pressure > 85 mmHg 10. Baseline quantitative methemoglobin measurement less than 2% 11. Creatinine less than the upper limit of normal Exclusion Criteria: 1. Female gender 2. Diagnosis of severe malaria 3. Presence of infection, or mixed infection, with non-falciparum strains of malaria 4. Signs of severe malaria[27], including 1 or more of the following: - impaired consciousness (Blantyre coma score <3 in children) - prostration - multiple convulsions (>2 within 24 hours) - acidosis (base deficit >8 mEq/L or bicarbonate <15 mmol/L or lactate > 5 mmol/L) - hypoglycemia (blood glucose < 40 mg/dL or <2.2 mmol/L) - severe anemia (Hb < 5g/dL ) - renal impairment (serum creatinine >265 uMol/L or 3 mg/dL; or blood urea >20 mmol/L) - jaundice (bilirubin >50 umol or 3 mg/dL with parasite count >100000/ µL) - pulmonary edema (including O2sat <92% with RR >30/min) - circulatory collapse or shock - significant bleeding - hyperparasitemia (>10%) 5. Presence of concomitant non-malarial infection 6. Known G6PD deficiency 7. Known chronic illness including renal, cardiac, pulmonary, epilepsy 8. History of a reaction to a substance or medication consisting of dyspnea and cyanosis 9. History of trauma or bleeding in the 2 weeks prior to presentation 10. Clinical impression of disseminated intravascular coagulation 11. Subjects treated with parenteral anti-malarial drugs for more than 12 hours 12. Current use of drugs with oxidative potential (e.g., nitrates, dapsone, primaquine); or drugs that cause hypotension. 13. Known allergic reactions to sodium nitrite injection |
Country | Name | City | State |
---|---|---|---|
Tanzania | Hubert Kairuki Memorial University | Dar es Salaam |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Heart, Lung, and Blood Institute (NHLBI) |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety as measured by number of subjects with at least one adverse event | Adverse events will be assessed according to the NIH's Table for Grading the Severity of Adult and Pediatric Adverse Events. Events will be numerically graded 1-5; 1 being a mild event and 5 being death | 48 hours post infusion | |
Primary | Percent change in microvascular function/activation for each of the 4 dosing levels by linear regression | We will assess possible covariate relationships. A model will be developed that links the pharmacokinetics with the pharmacodynamic measures of endothelial function and activation | 48 hours post infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00440752 -
The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance
|
N/A | |
Completed |
NCT01144702 -
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum
|
Phase 2/Phase 3 | |
Terminated |
NCT00400101 -
Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides
|
Phase 1 | |
Completed |
NCT01350856 -
Tracking Resistance to Artemisinin (TRAC)
|
Phase 4 | |
Completed |
NCT00859807 -
A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects
|
Phase 4 | |
Completed |
NCT04222088 -
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
|
||
Completed |
NCT01115439 -
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
|
N/A | |
Completed |
NCT00282919 -
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
|
Phase 2 | |
Completed |
NCT04422015 -
Biological Mechanisms in Afebrile P. Falciparum Malaria
|
||
Completed |
NCT00894660 -
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
|
Phase 1 | |
Completed |
NCT00894374 -
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
|
Phase 1 | |
Completed |
NCT00493363 -
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
|
N/A | |
Completed |
NCT00158548 -
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
|
Phase 3 | |
Completed |
NCT01374126 -
Azithromycin Combination Therapy for the Treatment of Severe Malaria
|
Phase 2 | |
Completed |
NCT00722150 -
Artemisinin Resistance in Cambodia II
|
N/A | |
Completed |
NCT00157833 -
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
|
N/A | |
Completed |
NCT00513669 -
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
|
Phase 1 | |
Completed |
NCT00403260 -
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
|
Phase 3 | |
Completed |
NCT00442377 -
Study to Investigate the Induction of an Protective Immune Response to Malaria
|
N/A | |
Completed |
NCT01365598 -
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
|
Phase 3 |